Spots Global Cancer Trial Database for metastatic tumor
Every month we try and update this database with for metastatic tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| HGS-ETR2 to Treat Children With Solid Tumors | NCT00428272 | Ewing's Sarcoma Osteosarcoma Neuroblastoma Rhabdomyosarcom... | Lexatumumab alo... Lexatumumab in ... Interferon gamm... Gamma 1b potent... | 1 Year - 30 Years | National Institutes of Health Clinical Center (CC) | |
| Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer | NCT05420519 | Metastatic Tumo... Renal Cell Carc... Advanced Cancer | CD70 CAR-T cell... | 18 Years - | Chongqing Precision Biotech Co., Ltd | |
| Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors | NCT05415475 | Colorectal Canc... Esophageal Canc... Stomach Cancer Pancreatic Canc... Metastatic Tumo... Recurrent Cance... | CEA CAR-T cells | 18 Years - | Chongqing Precision Biotech Co., Ltd | |
| Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors | NCT05415475 | Colorectal Canc... Esophageal Canc... Stomach Cancer Pancreatic Canc... Metastatic Tumo... Recurrent Cance... | CEA CAR-T cells | 18 Years - | Chongqing Precision Biotech Co., Ltd | |
| A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | NCT05731271 | Locally Advance... Metastatic Tumo... Colorectal Aden... | TST003 | 18 Years - | Suzhou Transcenta Therapeutics Co., Ltd. | |
| A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor. | NCT05717166 | Metastatic Tumo... | Palliative Radi... Chemotherapy Hormone therapy Immunotherapy Targeted System... Observation Stereotactic Ab... Surgery Radiofrequency ... Fractionated Ra... | 18 Years - | Lawson Health Research Institute | |
| A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors | NCT06383507 | Metastatic Tumo... Advanced Solid ... Renal Cell Carc... Ovarian Cancer Cervix Cancer Head and Neck S... Nasopharyngeal ... | CHT101 | 18 Years - 75 Years | Zhejiang University | |
| Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. | NCT02977156 | Metastatic Tumo... Advanced Tumor | Pexa-Vec Ipilimumab | 18 Years - | Centre Leon Berard | |
| A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread | NCT01648764 | Malignant Solid... Solid Tumor Metastatic Tumo... | LY2334737 | 18 Years - | Eli Lilly and Company | |
| A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors | NCT03238027 | Solid Tumor Metastatic Tumo... Locally Advance... Unresectable Ma... | Axatilimab Durvalumab | 18 Years - | Syndax Pharmaceuticals | |
| Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer | NCT05420519 | Metastatic Tumo... Renal Cell Carc... Advanced Cancer | CD70 CAR-T cell... | 18 Years - | Chongqing Precision Biotech Co., Ltd | |
| A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | NCT05731271 | Locally Advance... Metastatic Tumo... Colorectal Aden... | TST003 | 18 Years - | Suzhou Transcenta Therapeutics Co., Ltd. | |
| Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors | NCT05415475 | Colorectal Canc... Esophageal Canc... Stomach Cancer Pancreatic Canc... Metastatic Tumo... Recurrent Cance... | CEA CAR-T cells | 18 Years - | Chongqing Precision Biotech Co., Ltd | |
| Definitive Radiation for High-Risk Spine Metastases | NCT06165419 | Metastatic Canc... Metastatic Lung... Metastatic Brea... Metastatic Tumo... Metastatic Tumo... Metastatic Tumo... Spine Metastase... Metastasis | SBRT to the spi... | 18 Years - | Stony Brook University | |
| A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread | NCT01648764 | Malignant Solid... Solid Tumor Metastatic Tumo... | LY2334737 | 18 Years - | Eli Lilly and Company | |
| Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy | NCT05665348 | HCC - Hepatocel... Metastatic Canc... Metastatic Tumo... | Ipilimumab Inje... Atezolizumab In... Bevacizumab | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | NCT05099549 | Squamous Cell C... Carcinoma, Non-... Colorectal Neop... Advanced Solid ... Refractory Tumo... Metastatic Tumo... | AFM24 SNK01 | 18 Years - | NKGen Biotech, Inc. | |
| A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors | NCT05396300 | Colorectal Canc... Esophageal Canc... Stomach Cancer Pancreatic Canc... Metastatic Tumo... Recurrent Cance... | CEA CAR-T cells | 18 Years - | Zhejiang University | |
| Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | NCT05099549 | Squamous Cell C... Carcinoma, Non-... Colorectal Neop... Advanced Solid ... Refractory Tumo... Metastatic Tumo... | AFM24 SNK01 | 18 Years - | NKGen Biotech, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
